Simons Mikael, Levin Johannes, Dichgans Martin
Institute of Neuronal Cell Biology, Technical University Munich, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster of Systems Neurology (SyNergy), Munich, Germany; Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster of Systems Neurology (SyNergy), Munich, Germany; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.
Neuron. 2023 Oct 4;111(19):2954-2968. doi: 10.1016/j.neuron.2023.05.031. Epub 2023 Jun 28.
In Alzheimer's disease (AD), Aβ deposits form slowly, several decades before further pathological events trigger neurodegeneration and dementia. However, a substantial proportion of affected individuals remains non-demented despite AD pathology, raising questions about the underlying factors that determine the transition to clinical disease. Here, we emphasize the critical function of resilience and resistance factors, which we extend beyond the concept of cognitive reserve to include the glial, immune, and vascular system. We review the evidence and use the metaphor of "tipping points" to illustrate how gradually forming AD neuropathology in the preclinical stage can transition to dementia once adaptive functions of the glial, immune, and vascular system are lost and self-reinforcing pathological cascades are unleashed. Thus, we propose an expanded framework for pathomechanistic research that focuses on tipping points and non-neuronal resilience mechanisms, which may represent previously untapped therapeutic targets in preclinical AD.
在阿尔茨海默病(AD)中,β-淀粉样蛋白(Aβ)沉积形成缓慢,在进一步的病理事件引发神经退行性变和痴呆症的几十年前就已开始。然而,尽管存在AD病理改变,但仍有相当一部分受影响个体未出现痴呆症状,这引发了人们对决定向临床疾病转变的潜在因素的质疑。在此,我们强调了恢复力和抵抗因素的关键作用,我们将其概念扩展到认知储备之外,涵盖神经胶质、免疫和血管系统。我们回顾了相关证据,并使用“临界点”这一比喻来说明临床前期逐渐形成的AD神经病理学如何在神经胶质、免疫和血管系统的适应性功能丧失且自我强化的病理级联反应被触发后转变为痴呆症。因此,我们提出了一个扩展的病理机制研究框架,该框架聚焦于临界点和非神经元恢复力机制,这些机制可能代表了临床前期AD中尚未开发的治疗靶点。